DDInter596 DDInter1281
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is downregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is palliated by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is bound by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is downregulated by Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Doxorubicin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is palliated by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Neratinib